290 related articles for article (PubMed ID: 11589723)
1. Serum chromogranin A as a screening test for gastric enterochromaffin-like cell hyperplasia during acid-suppressive therapy.
Sanduleanu S; De Bruïne A; Stridsberg M; Jonkers D; Biemond I; Hameeteman W; Lundqvist G; Stockbrügger RW
Eur J Clin Invest; 2001 Sep; 31(9):802-11. PubMed ID: 11589723
[TBL] [Abstract][Full Text] [Related]
2. Serum gastrin and chromogranin A during medium- and long-term acid suppressive therapy: a case-control study.
Sanduleanu S; Stridsberg M; Jonkers D; Hameeteman W; Biemond I; Lundqvist G; Lamers C; Stockbrügger RW
Aliment Pharmacol Ther; 1999 Feb; 13(2):145-53. PubMed ID: 10102943
[TBL] [Abstract][Full Text] [Related]
3. The gastric mucosa 25 years after proximal gastric vagotomy.
Sagatun L; Jianu CS; Fossmark R; Mårvik R; Nordrum IS; Waldum HL
Scand J Gastroenterol; 2014 Oct; 49(10):1173-80. PubMed ID: 25157752
[TBL] [Abstract][Full Text] [Related]
4. Gastric exocrine and endocrine cell morphology under prolonged acid inhibition therapy: results of a 5-year follow-up in the LOTUS trial.
Fiocca R; Mastracci L; Attwood SE; Ell C; Galmiche JP; Hatlebakk J; Bärthel A; Långström G; Lind T; Lundell L;
Aliment Pharmacol Ther; 2012 Nov; 36(10):959-71. PubMed ID: 22998687
[TBL] [Abstract][Full Text] [Related]
5. Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids.
Peracchi M; Gebbia C; Basilisco G; Quatrini M; Tarantino C; Vescarelli C; Massironi S; Conte D
Eur J Endocrinol; 2005 Mar; 152(3):443-8. PubMed ID: 15757862
[TBL] [Abstract][Full Text] [Related]
6. Helicobacter pylori effects on gastritis, gastrin and enterochromaffin-like cells in Zollinger-Ellison syndrome and non-Zollinger-Ellison syndrome acid hypersecretors treated long-term with lansoprazole.
Hirschowitz BI; Haber MM
Aliment Pharmacol Ther; 2001 Jan; 15(1):87-103. PubMed ID: 11136282
[TBL] [Abstract][Full Text] [Related]
7. Neuroendocrine tumor markers and enterochromaffin-like cell hyper/dysplasia in type 1 diabetes.
De Block CE; Colpin G; Thielemans K; Coopmans W; Bogers JJ; Pelckmans PA; Van Marck EA; Van Hoof V; Martin M; De Leeuw IH; Bouillon R; Van Gaal LF
Diabetes Care; 2004 Jun; 27(6):1387-93. PubMed ID: 15161793
[TBL] [Abstract][Full Text] [Related]
8. Serum gastrin and chromogranin A levels in patients with fundic gland polyps caused by long-term proton-pump inhibition.
Fossmark R; Jianu CS; Martinsen TC; Qvigstad G; Syversen U; Waldum HL
Scand J Gastroenterol; 2008 Jan; 43(1):20-4. PubMed ID: 18938772
[TBL] [Abstract][Full Text] [Related]
9. Marked increase in gastric acid secretory capacity after omeprazole treatment.
Waldum HL; Arnestad JS; Brenna E; Eide I; Syversen U; Sandvik AK
Gut; 1996 Nov; 39(5):649-53. PubMed ID: 9026477
[TBL] [Abstract][Full Text] [Related]
10. Effects of 5 years of treatment with rabeprazole or omeprazole on the gastric mucosa.
Rindi G; Fiocca R; Morocutti A; Jacobs A; Miller N; Thjodleifsson B;
Eur J Gastroenterol Hepatol; 2005 May; 17(5):559-66. PubMed ID: 15827447
[TBL] [Abstract][Full Text] [Related]
11. A meal test improves the specificity of chromogranin A as a marker of neuroendocrine neoplasia.
Jianu CS; Fossmark R; Syversen U; Hauso Ø; Waldum HL
Tumour Biol; 2010 Oct; 31(5):373-80. PubMed ID: 20480408
[TBL] [Abstract][Full Text] [Related]
12. Gastric cancer and gastrin: on the interaction of Helicobacter pylori gastritis and acid inhibitory induced hypergastrinemia.
Waldum HL; Rehfeld JF
Scand J Gastroenterol; 2019 Sep; 54(9):1118-1123. PubMed ID: 31524029
[TBL] [Abstract][Full Text] [Related]
13. Systematic review: the effects of long-term proton pump inhibitor use on serum gastrin levels and gastric histology.
Lundell L; Vieth M; Gibson F; Nagy P; Kahrilas PJ
Aliment Pharmacol Ther; 2015 Sep; 42(6):649-63. PubMed ID: 26177572
[TBL] [Abstract][Full Text] [Related]
14. Ratio between serum IL-8 and pepsinogen A/C: a marker for atrophic body gastritis.
Sanduleanu S; Bruïne AD; Biemond I; Stridsberg M; Jonkers D; Lundqvist G; Hameeteman W; Stockbrügger RW
Eur J Clin Invest; 2003 Feb; 33(2):147-54. PubMed ID: 12588289
[TBL] [Abstract][Full Text] [Related]
15. Serum chromogranin A level continuously rises with the progression of type 1 diabetes, and indicates the presence of both enterochromaffin-like cell hyperplasia and autoimmune gastritis.
Herold Z; Herold M; Nagy P; Patocs A; Doleschall M; Somogyi A
J Diabetes Investig; 2020 Jul; 11(4):865-873. PubMed ID: 31883432
[TBL] [Abstract][Full Text] [Related]
16. Treatment of ECL cell carcinoids with octreotide LAR.
Fykse V; Sandvik AK; Qvigstad G; Falkmer SE; Syversen U; Waldum HL
Scand J Gastroenterol; 2004 Jul; 39(7):621-8. PubMed ID: 15370681
[TBL] [Abstract][Full Text] [Related]
17. Randomised trial of the effect of a gastrin/CCK
Boyce M; van den Berg F; Mitchell T; Darwin K; Warrington S
Eur J Clin Pharmacol; 2017 Feb; 73(2):129-139. PubMed ID: 27796466
[TBL] [Abstract][Full Text] [Related]
18. Hypergastrinemia and enterochromaffin-like cell hyperplasia.
Delle Fave G; Marignani M; Moretti A; D'Ambra G; Martino G; Annibale B
Yale J Biol Med; 1998; 71(3-4):291-301. PubMed ID: 10461360
[TBL] [Abstract][Full Text] [Related]
19. [Effect of prolonged treatment with proton pump inhibitors on serum gastrin levels and the fundus mucosa. Preliminary results].
Cadiot G; Vissuzaine C; Pospai D; Ruszniewski P; Potet F; Mignon M
Gastroenterol Clin Biol; 1995 Oct; 19(10):811-7. PubMed ID: 8566561
[TBL] [Abstract][Full Text] [Related]
20. Effect of proton-pump inhibitor therapy on serum chromogranin a level.
Pregun I; Herszényi L; Juhász M; Miheller P; Hritz I; Patócs A; Rácz K; Tulassay Z
Digestion; 2011; 84(1):22-8. PubMed ID: 21304238
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
